Thus, one rational approach to reduce seizures in AD is inhibition of BACE1, the rate-limiting enzyme for Aβ generation, whose inhibition has been shown to reduce amyloid deposition in both preclinical AD mouse models and clinical studies (Hampel et al., 2021). This evidence concerns the gene BACE1 and Alzheimer disease.